FindTrial
Sign In

To compare a new and easy way ( CET score) with the traditional way(RegiSCAR) in patients of drug allergy.

To validate CET score in patients of DRESS syndrome vs RegiSCAR as gold standard

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2021/11/038121
Enrollment
100
Registered
2021-11-18
Start date
Unknown
Completion date
Unknown
Last updated
2022-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L270- Generalized skin eruption due to drugs and medicaments taken internally

Interventions

None listed

Sponsors

Sukhdeep Singh
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: patients giving consent, All maculopapular drug rash patients

Exclusion criteria

Exclusion criteria: Patients in sepsis, admitted in ICU for other acute illnesses ,SCAR other than DRESS including erythema multiforme, steven johnson syndrome, toxic epidermal necrolysis, drug induced vasculitis and acute generalized exanthematous pustulosis. Patients not giving consent.

Design outcomes

Primary

MeasureTime frame
To validate CET score in patients of DRESS Syndrome Vs RegiSCAR as gold standard by assessing sensitivity,specificity and predictive valueTimepoint: 1.5 years—

Secondary

MeasureTime frame
(a) To find lead time advantage in diagnosis of DRESS using CET score Vs RegiSCAR. (b) To assess the cost-benefit in terms of cost of tests, costs of in patient admission, loss of work and commute between two scores. Timepoint: 1.5 years—

Countries

India

Contacts

Public ContactSukhdeep Singh

PGIMER Chandigarh

drsen_2000@yahoo.com8872004023

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026